Telix's NDA for TLX101-Px Accepted by FDA, PDUFA Date Set
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy TLX?
Source: Newsfilter
- FDA Acceptance: Telix Pharmaceuticals announced that the FDA has accepted its New Drug Application for TLX101-Px, with a PDUFA goal date set for September 11, 2026, marking a significant advancement in brain tumor imaging and addressing critical medical needs for recurrent or progressive glioma in both adult and pediatric patients.
- Clinical Need Fulfillment: TLX101-Px, a PET imaging agent, has received Orphan Drug and Fast Track designations from the FDA, enabling better differentiation between tumor progression and treatment-related changes, which is crucial for improving treatment outcomes and survival rates for glioma patients.
- International Recognition: The imaging technology is widely recommended in international clinical practice guidelines, particularly the NCCN guidelines, highlighting its potential for clinical application globally and enhancing Telix's market position in tumor imaging.
- Future Outlook: Telix does not anticipate any revenue contribution from TLX101-Px in FY 2026; however, the FDA's acceptance lays the groundwork for future market launch, with the CEO expressing commitment to work closely with the FDA to expedite approval and commercialization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Telix's NDA for TLX101-Px Accepted by FDA, PDUFA Date Set
- FDA Acceptance: Telix Pharmaceuticals announced that the FDA has accepted its New Drug Application for TLX101-Px, with a PDUFA goal date set for September 11, 2026, marking a significant advancement in brain tumor imaging and addressing critical medical needs for recurrent or progressive glioma in both adult and pediatric patients.
- Clinical Need Fulfillment: TLX101-Px, a PET imaging agent, has received Orphan Drug and Fast Track designations from the FDA, enabling better differentiation between tumor progression and treatment-related changes, which is crucial for improving treatment outcomes and survival rates for glioma patients.
- International Recognition: The imaging technology is widely recommended in international clinical practice guidelines, particularly the NCCN guidelines, highlighting its potential for clinical application globally and enhancing Telix's market position in tumor imaging.
- Future Outlook: Telix does not anticipate any revenue contribution from TLX101-Px in FY 2026; however, the FDA's acceptance lays the groundwork for future market launch, with the CEO expressing commitment to work closely with the FDA to expedite approval and commercialization.
See More
Telix's NDA for TLX101-Px Accepted by FDA, PDUFA Date Set
- FDA Application Progress: Telix Pharmaceuticals announced that its NDA for TLX101-Px has been accepted by the FDA, with a PDUFA goal date set for September 11, 2026, marking a significant milestone in addressing imaging needs for brain tumors.
- Meeting Market Demand: The approval of TLX101-Px will fulfill a critical need for imaging recurrent or progressive glioma in both adult and pediatric patients post-treatment, which is expected to significantly enhance patient management in clinical practice.
- Clinical Application Prospects: The drug has received Orphan Drug and Fast Track designations from the FDA, indicating its recommended status in international clinical guidelines, which may drive its widespread adoption in the U.S. market.
- Strategic Importance for Company: Telix's CEO stated that the FDA's acceptance is a crucial milestone for the company, which will expedite the product's market entry to meet patient medical needs and enhance the company's position in the oncology imaging sector.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
Telix Pharmaceuticals Reports Q1 Revenue Growth of 23.7%
- Significant Revenue Growth: Telix Pharmaceuticals reported Q1 revenue of $230 million, reflecting a 23.7% year-over-year increase, which demonstrates the company's strong market performance and sustained product demand, further solidifying its position in the healthcare sector.
- 2026 Revenue Guidance: The company reaffirms its FY 2026 revenue guidance of $950 million to $970 million, exceeding the consensus estimate of $943.10 million, indicating Telix's confidence in future product sales and marketing authorizations, which is expected to drive long-term growth.
- R&D Expenditure Plans: Telix anticipates R&D expenditures between $200 million and $240 million for FY 2026, aimed at supporting the achievement of global commercial milestones, which will lay the groundwork for future innovations and product development.
- Market Expansion Strategy: Telix is actively expanding its prostate cancer imaging portfolio and plans to enter brain and kidney cancer markets, a strategy that not only diversifies its product line but also enhances the company's competitiveness in the cancer treatment market.
See More
Telix Pharmaceuticals Reports 24% Revenue Growth in Q1
- Significant Revenue Growth: Telix Pharmaceuticals reported Q1 2026 revenue of $230 million, a 24% increase from $186 million in the prior year, indicating strong performance in precision medicine, particularly driven by the Illuccix and Gozellix product lines.
- Guidance Reaffirmation: The company reaffirmed its full-year revenue guidance for 2026 at $950 million to $970 million, reflecting confidence in future growth and further solidifying its position in the biopharmaceutical market.
- Clinical Trial Progress: The Phase 3 trial of TLX591 (ProstACT GLOBAL) successfully met its study objectives with no new safety signals observed, highlighting the drug's potential in treating prostate cancer and paving the way for future FDA approvals.
- Strong Cash Position: Telix reported a year-end cash balance of $141.9 million for 2025, ensuring sufficient funding for future R&D and marketing efforts, thereby enhancing its financial stability.
See More
Telix's NDA for TLX101-Px Accepted by FDA, PDUFA Date Set
- FDA Acceptance: Telix Pharmaceuticals announced that the FDA has accepted its New Drug Application for TLX101-Px, with a PDUFA goal date set for September 11, 2026, marking a significant advancement in brain tumor imaging and addressing critical medical needs for recurrent or progressive glioma in both adult and pediatric patients.
- Clinical Need Fulfillment: TLX101-Px, a PET imaging agent, has received Orphan Drug and Fast Track designations from the FDA, enabling better differentiation between tumor progression and treatment-related changes, which is crucial for improving treatment outcomes and survival rates for glioma patients.
- International Recognition: The imaging technology is widely recommended in international clinical practice guidelines, particularly the NCCN guidelines, highlighting its potential for clinical application globally and enhancing Telix's market position in tumor imaging.
- Future Outlook: Telix does not anticipate any revenue contribution from TLX101-Px in FY 2026; however, the FDA's acceptance lays the groundwork for future market launch, with the CEO expressing commitment to work closely with the FDA to expedite approval and commercialization.
See More
Telix's NDA for TLX101-Px Accepted by FDA, PDUFA Date Set
- FDA Application Progress: Telix Pharmaceuticals announced that its NDA for TLX101-Px has been accepted by the FDA, with a PDUFA goal date set for September 11, 2026, marking a significant milestone in addressing imaging needs for brain tumors.
- Meeting Market Demand: The approval of TLX101-Px will fulfill a critical need for imaging recurrent or progressive glioma in both adult and pediatric patients post-treatment, which is expected to significantly enhance patient management in clinical practice.
- Clinical Application Prospects: The drug has received Orphan Drug and Fast Track designations from the FDA, indicating its recommended status in international clinical guidelines, which may drive its widespread adoption in the U.S. market.
- Strategic Importance for Company: Telix's CEO stated that the FDA's acceptance is a crucial milestone for the company, which will expedite the product's market entry to meet patient medical needs and enhance the company's position in the oncology imaging sector.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
Telix Pharmaceuticals Reports Q1 Revenue Growth of 23.7%
- Significant Revenue Growth: Telix Pharmaceuticals reported Q1 revenue of $230 million, reflecting a 23.7% year-over-year increase, which demonstrates the company's strong market performance and sustained product demand, further solidifying its position in the healthcare sector.
- 2026 Revenue Guidance: The company reaffirms its FY 2026 revenue guidance of $950 million to $970 million, exceeding the consensus estimate of $943.10 million, indicating Telix's confidence in future product sales and marketing authorizations, which is expected to drive long-term growth.
- R&D Expenditure Plans: Telix anticipates R&D expenditures between $200 million and $240 million for FY 2026, aimed at supporting the achievement of global commercial milestones, which will lay the groundwork for future innovations and product development.
- Market Expansion Strategy: Telix is actively expanding its prostate cancer imaging portfolio and plans to enter brain and kidney cancer markets, a strategy that not only diversifies its product line but also enhances the company's competitiveness in the cancer treatment market.
See More
Telix Pharmaceuticals Reports 24% Revenue Growth in Q1
- Significant Revenue Growth: Telix Pharmaceuticals reported Q1 2026 revenue of $230 million, a 24% increase from $186 million in the prior year, indicating strong performance in precision medicine, particularly driven by the Illuccix and Gozellix product lines.
- Guidance Reaffirmation: The company reaffirmed its full-year revenue guidance for 2026 at $950 million to $970 million, reflecting confidence in future growth and further solidifying its position in the biopharmaceutical market.
- Clinical Trial Progress: The Phase 3 trial of TLX591 (ProstACT GLOBAL) successfully met its study objectives with no new safety signals observed, highlighting the drug's potential in treating prostate cancer and paving the way for future FDA approvals.
- Strong Cash Position: Telix reported a year-end cash balance of $141.9 million for 2025, ensuring sufficient funding for future R&D and marketing efforts, thereby enhancing its financial stability.
See More
